Y-Intercept (HK)’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$767K Buy
70,973
+35,131
+98% +$315K 0.02% 1120
2026
Q2
$338K Buy
+35,842
New +$321K 0.01% 1429
2022
Q3
– Sell
-5,115
Closed -$263K – 1180
2022
Q2
$263K Buy
+5,115
New +$265K 0.03% 626
2021
Q3
– Sell
-5,617
Closed -$1.19M – 832
2021
Q2
$1.19M Buy
5,617
+3,454
+160% +$633K 0.3% 65
2021
Q1
$375K Buy
2,163
+75
+4% +$14.9K 0.1% 325
2020
Q4
$248K Buy
+2,088
New +$222K 0.1% 375

Other funds holding NVAX

Y-Intercept (HK)'s NVAX Position: Q3 2026 in Review

Y-Intercept (HK) increased its Novavax (NVAX) stake by 98% in Q3 2026, buying an estimated $315K and bringing the position to 70,973 shares worth $767K. The position accounts for 0.02% of the portfolio, ranked #1120.

Y-Intercept (HK) first reported a position in NVAX in Q4 2020 and has held it in 6 quarters since. The position peaked at $1.19M in Q2 2021. 56 funds tracked by Wall St. Rank hold NVAX as of Q3 2026.

  • Y-Intercept (HK) held 70,973 shares of Novavax worth $767K as of Q3 2026.
  • Y-Intercept (HK) bought 35,131 Novavax shares in Q3 2026, an estimated $315K.
  • Novavax made up 0.02% of Y-Intercept (HK)'s portfolio in Q3 2026, its #1120 holding.
  • Y-Intercept (HK) first reported a position in Novavax in Q4 2020 and has held it in 6 quarters since.
  • Y-Intercept (HK)'s Novavax position peaked at $1.19M in Q2 2021.
  • 56 funds tracked by Wall St. Rank held Novavax as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.